Category: Federal Forum Posters
Purpose: Continuous glucose monitors (CGM) deliver blood glucose data every 5 minutes, provide low and high glucose alerts, and relay glucose trends. Studies indicate that use of CGM significantly reduces hypoglycemic events, improves glycosylated hemoglobin (A1c), and reduce glucose variability in some individuals with DM; however, the clinical effect of these devices in veterans within VA-Boston has not been evaluated. The primary objective of this study is to determine the effect of CGM use on hemoglobin A1c in adult veterans with diabetes mellitus. Secondary objectives analyzed include the percentage of time blood glucose is in range and frequency of hypoglycemic events.
Methods: This pilot analysis will evaluate 23 veterans with insulin dependent diabetes that acquired a personal CGM through VA Boston. A retrospective chart review will be conducted using data from the Veterans Affairs Boston Healthcare System computerized records (CPRS). Baseline data collected will include date of initiation of CGM, A1c within 3 months of CGM start, age, eGFR, and BMI. A1c collected at 3 months, 6 months, and 12 months after device start will be compared to baseline A1c. Data from the CGM output will be used to evaluate percentage of time in glucose range, and number of hypoglycemic episodes. Goal glucose range will be defined as 70-180 mg/dL and hypoglycemia will be defined as blood glucose less than 70mg/dL. Results will be analyzing using a repeated measures linear regression model assessing the change in A1c over time and accounting for age, BMI, and renal function.
Results: not applicable
Conclusion: not applicable
Jacqueline Chrones– P4 Pharmacy Student, Northeastern University, Boston, MA